Hoth Therapeutics, a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, as well as dermatological and chronic wound disorders, has signed contracts with providers for production of their BioLexa therapeutic, in preparation for upcoming toxicology and clinical studies.   Hoth has begun preparations for the testing of its formulation for both active and vehicle stability. The company has engaged...